Abstract
The dual hypocretin receptor (HcrtR) antagonist almorexant (ALM) may promote sleep through selective disfacilitation of wake-promoting systems, whereas benzodiazepine receptor agonists (BzRAs) such as zolpidem (ZOL) induce sleep through general inhibition of neural activity. Previous studies have indicated that HcrtR antagonists cause less-functional impairment than BzRAs. To gain insight into the mechanisms underlying these differential profiles, we compared the effects of ALM and ZOL on functional activation of wake-promoting systems at doses equipotent for sleep induction. Sprague-Dawley rats, implanted for EEG/EMG recording, were orally administered vehicle (VEH), 100 mg/kg ALM, or 100 mg/kg ZOL during their active phase and either left undisturbed or kept awake for 90 min after which their brains were collected. ZOL-treated rats required more stimulation to maintain wakefulness than VEH- or ALM-treated rats. We measured Fos co-expression with markers for wake-promoting cell groups in the lateral hypothalamus (Hcrt), tuberomammillary nuclei (histamine; HA), basal forebrain (acetylcholine; ACh), dorsal raphe (serotonin; 5HT), and singly labeled Fos+ cells in the locus coeruleus (LC). Following SD, Fos co-expression in Hcrt, HA, and ACh neurons (but not in 5HT neurons) was consistently elevated in VEH- and ALM-treated rats, whereas Fos expression in these neuronal groups was unaffected by SD in ZOL-treated rats. Surprisingly, Fos expression in the LC was elevated in ZOL- but not in VEH- or ALM-treated SD animals. These results indicate that Hcrt signaling is unnecessary for the activation of Hcrt, HA, or ACh wake-active neurons, which may underlie the milder cognitive impairment produced by HcrtR antagonists compared to ZOL.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Balkin TJ, O'Donnell VM, Wesensten N, McCann U, Belenky G (1992). Comparison of the daytime sleep and performance effects of zolpidem versus triazolam. Psychopharmacology 107: 83–88.
Bayer L, Eggermann E, Serafin M, Saint-Mleux B, Machard D, Jones B et al (2001). Orexins (hypocretins) directly excite tuberomammillary neurons. Eur J Neurosci 14: 1571–1575.
Blouin AM, Fried I, Wilson CL, Staba RJ, Behnke EJ, Lam HA et al (2013). Human hypocretin and melanin-concentrating hormone levels are linked to emotion and social interaction. Nat Commun 4: 1547.
Brisbare-Roch C, Dingemanse J, Koberstein R, Hoever P, Aissaoui H, Flores S et al (2007). Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med 13: 150–155.
Brown RE, Basheer R, McKenna JT, Strecker RE, McCarley RW (2012). Control of sleep and wakefulness. Physiol Rev 92: 1087–1187.
Carter ME, Brill J, Bonnavion P, Huguenard JR, Huerta R, de Lecea L (2012). Mechanism for Hypocretin-mediated sleep-to-wake transitions. Proc Natl Acad Sci USA 109: e2635–e2644.
Chen CS, Huang MF, Hwang TJ, Chen ST, Ko CH, Yen CN et al (2014). Clinical correlates of zolpidem-associated complex sleep-related behaviors: age effect. J Clin Psychiatry 75: e1314–e1318.
Cox CD, Breslin MJ, Whitman DB, Schreier JD, McGaughey GB, Bogusky MJ et al (2010). Discovery of the dual orexin receptor antagonist [(7 R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methy l-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J Med Chem 53: 5320–5332.
de Lecea L, Kilduff TS, Peyron C, Gao X-B, Foye PE, Danielson PE et al (1998). The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 95: 322–327.
Deurveilher S, Lo H, Murphy JA, Burns J, Semba K (2006). Differential c-Fos immunoreactivity in arousal-promoting cell groups following systemic administration of caffeine in rats. J Comp Neurol 498: 667–689.
Deurveilher S, Ryan N, Burns J, Semba K (2013). Social and environmental contexts modulate sleep deprivation-induced c-Fos activation in rats. Behav Brain Res 256: 238–249.
Dietrich H, Jenck F (2010). Intact learning and memory in rats following treatment with the dual orexin receptor antagonist almorexant. Psychopharmacology 212: 145–154.
Dittrich L, Morairty SR, Warrier DR, Kilduff TS (2015). Homeostatic sleep pressure is the primary factor for activation of cortical nNOS/NK1 neurons. Neuropsychopharmacology 40: 632–639.
Dolder CR, Nelson MH (2008). Hypnosedative-induced complex behaviours: incidence, mechanisms and management. CNS Drugs 22: 1021–1036.
Dugovic C, Shelton JE, Aluisio LE, Fraser IC, Jiang X, Sutton SW et al (2009). Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J Pharmacol Exp Ther 330: 142–151.
Eggermann E, Serafin M, Bayer L, Machard D, Saint-Mleux B, Jones BE et al (2001). Orexins/hypocretins excite basal forebrain cholinergic neurones. Neuroscience 108: 177–181.
Ericson H, Watanabe T, Kohler C (1987). Morphological analysis of the tuberomammillary nucleus in the rat brain: delineation of subgroups with antibody against L-histidine decarboxylase as a marker. J Comp Neurol 263: 1–24.
Eriksson KS, Sergeeva O, Brown RS, Haas HL (2001). Orexin/hypocretin excites the histaminergic neurons of the tuberomammillary nucleus. J Neurosci 21: 9273–9279.
Eriksson KS, Sergeeva OA, Selbach O, Haas HL (2004). Orexin (hypocretin)/dynorphin neurons control GABAergic inputs to tuberomammillary neurons. Eur J Neurosci 19: 1278–1284.
Espana RA, Valentino RJ, Berridge CW (2003). Fos immunoreactivity in hypocretin-synthesizing and hypocretin-1 receptor-expressing neurons: effects of diurnal and nocturnal spontaneous waking, stress and hypocretin-1 administration. Neuroscience 121: 201–217.
Greenblatt DJ, Roth T (2012). Zolpidem for insomnia. Expert Opin Pharmacother 13: 879–893.
Gunja N (2013). In the Zzz zone: the effects of Z-drugs on human performance and driving. J Med Toxicol 9: 163–171.
Hara J, Beuckmann CT, Nambu T, Willie JT, Chemelli RM, Sinton CM et al (2001). Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30: 345–354.
Harris GC, Aston-Jones G (2006). Arousal and reward: a dichotomy in orexin function. Trends Neurosci 29: 571–577.
Henny P, Brischoux F, Mainville L, Stroh T, Jones BE (2010). Immunohistochemical evidence for synaptic release of glutamate from orexin terminals in the locus coeruleus. Neuroscience 169: 1150–1157.
Hoever P, de Haas S, Winkler J, Schoemaker RC, Chiossi E, van Gerven J et al (2010). Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant. Clin Pharmacol Ther 87: 593–600.
Hoever P, de Haas SL, Dorffner G, Chiossi E, van Gerven JM, Dingemanse J (2012). Orexin receptor antagonism: an ascending multiple-dose study with almorexant. J Psychopharmacol 26: 1071–1080.
Huang MP, Radadia K, Macone BW, Auerbach SH, Datta S (2010). Effects of eszopiclone and zolpidem on sleep-wake behavior, anxiety-like behavior and contextual memory in rats. Behav Brain Res 210: 54–66.
Jacobson LH, Callander GE, Hoyer D (2014). Suvorexant for the treatment of insomnia. Expert Rev Clin P 7: 711–730.
Jones BE (2003). Arousal systems. Front Biosci 8: s438–s451.
Ko EM, Estabrooke IV, McCarthy M, Scammell TE (2003). Wake-related activity of tuberomammillary neurons in rats. Brain Res 992: 220–226.
Koberstein R, Aissaoui H, Bur D, Clozel M, Fischli W, Jenck F et al (2003). Tetrahydroisoquinolines as orexin receptor antagonists: strategies for lead optimization by solution-phase chemistry. Chimia 57: 270–275.
Koberstein R, Fischll W, Clozel M, Aissaou H, Weller T (2005) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives. In: WIPO (ed). WIPO. Actelion Pharm. LTD.
Lamond N, Jay SM, Dorrian J, Ferguson SA, Jones C, Dawson D (2007). The dynamics of neurobehavioural recovery following sleep loss. J Sleep Res 16: 33–41.
Lee MG, Hassani OK, Jones BE (2005). Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. J Neurosci 25: 6716–6720.
Lee SB, Chang BJ, Lee HS (2008). Organization of histamine-immunoreactive, tuberomammillary neurons projecting to the dorsal tier of the substantia nigra compacta in the rat. Brain Res 1203: 79–88.
Li X, Marchant NJ, Shaham Y (2014). Opposing roles of cotransmission of dynorphin and hypocretin on reward and motivation. Proc Natl Acad Sci USA 111: 5765–5766.
Li Y, Gao XB, Sakurai T, van den Pol AN (2002). Hypocretin/Orexin excites hypocretin neurons via a local glutamate neuron-A potential mechanism for orchestrating the hypothalamic arousal system. Neuron 36: 1169–1181.
Li Y, van den Pol AN (2005). Direct and indirect inhibition by catecholamines of hypocretin/orexin neurons. J Neurosci 25: 173–183.
Liu RJ, van den Pol AN, Aghajanian GK (2002). Hypocretins (orexins) regulate serotonin neurons in the dorsal raphe nucleus by excitatory direct and inhibitory indirect actions. J Neurosci 22: 9453–9464.
Mai E, Buysse DJ (2008). Insomnia: prevalence, impact, pathogenesis, differential diagnosis, and evaluation. Sleep Med Clin 3: 167–174.
Marcus JN, Aschkenasi CJ, Lee CE, Chemelli RM, Saper CB, Yanagisawa M et al (2001). Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol 435: 6–25.
McKenna JT, Cordeira JW, Jeffrey BA, Ward CP, Winston S, McCarley RW et al (2009). c-Fos protein expression is increased in cholinergic neurons of the rodent basal forebrain during spontaneous and induced wakefulness. Brain Res Bull 80: 382–388.
Mintzer MZ, Griffiths RR (1999). Selective effects of zolpidem on human memory functions. J Psychopharmacol 13: 18–31.
Morairty SR, Dittrich L, Pasumarthi RK, Valladao D, Heiss JE, Gerashchenko D et al (2013). A role for cortical nNOS/NK1 neurons in coupling homeostatic sleep drive to EEG slow wave activity. Proc Natl Acad Sci USA 110: 20272–20277.
Morairty SR, Hedley L, Flores J, Martin R, Kilduff TS (2008). Selective 5HT2A and 5HT6 receptor antagonists promote sleep in rats. Sleep 31: 34–44.
Morairty SR, Revel FG, Malherbe P, Moreau JL, Valladao D, Wettstein JG et al (2012). Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone. PLoS One 7: e39131.
Morairty SR, Wilk AJ, Lincoln WU, Neylan TC, Kilduff TS (2014). The hypocretin/orexin antagonist almorexant promotes sleep without impairment of performance in rats. Front Neurosci 8: 3.
Muschamp JW, Hollander JA, Thompson JL, Voren G, Hassinger LC, Onvani S et al (2014). Hypocretin (orexin) facilitates reward by attenuating the antireward effects of its cotransmitter dynorphin in ventral tegmental area. Proc Natl Acad Sci USA 111: e1648–e1655.
Paxinos G, Watson C (2005) The Rat Brain in Stereotaxic Coordinates, 5th edn. Elsevier Academic Press: Amsterdam; Boston, xliii p, 166 pp.
Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, Sutcliffe JG et al (1998). Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 18: 9996–10015.
Ramirez AD, Gotter AL, Fox SV, Tannenbaum PL, Yao L, Tye SJ et al (2013). Dual orexin receptor antagonists show distinct effects on locomotor performance, ethanol interaction and sleep architecture relative to gamma-aminobutyric acid-A receptor modulators. Front Neurosci 7: 254.
Roecker AJ, Coleman PJ (2008). Orexin receptor antagonists: medicinal chemistry and therapeutic potential. Curr Top Med Chem 8: 977–987.
Roth T (2007). Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med 3 (5 Suppl): S7–S10.
Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H et al (1998). Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92: 1 page following 696.
Sakurai T, Nagata R, Yamanaka A, Kawamura H, Tsujino N, Muraki Y et al (2005). Input of orexin/hypocretin neurons revealed by a genetically encoded tracer in mice. Neuron 46: 297–308.
Saper CB, Chou TC, Scammell TE (2001). The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci 24: 726–731.
Schone C, Apergis-Schoute J, Sakurai T, Adamantidis A, Burdakov D (2014). Coreleased orexin and glutamate evoke nonredundant spike outputs and computations in histamine neurons. Cell Rep 7: 697–704.
Schone C, Cao ZF, Apergis-Schoute J, Adamantidis A, Sakurai T, Burdakov D (2012). Optogenetic probing of fast glutamatergic transmission from hypocretin/orexin to histamine neurons in situ. J Neurosci 32: 12437–12443.
Schwartz JC, Arrang JM, Garbarg M, Pollard H, Ruat M (1991). Histaminergic transmission in the mammalian brain. Physiol Rev 71: 1–51.
Steiner MA, Lecourt H, Strasser DS, Brisbare-Roch C, Jenck F (2011). Differential effects of the dual orexin receptor antagonist almorexant and the GABA(A)-alpha1 receptor modulator zolpidem, alone or combined with ethanol, on motor performance in the rat. Neuropsychopharmacology 36: 848–856.
Storm WF, Eddy DR, Welch CB, Hickey PA, Fischer J, Cardenas R (2007). Cognitive performance following premature awakening from zolpidem or melatonin induced daytime sleep. Aviation space Environ Med 78: 10–20.
Sved AF, Cano G, Passerin AM, Rabin BS (2002). The locus coeruleus, Barrington's nucleus, and neural circuits of stress. Physiol Behav 77: 737–742.
Tannenbaum PL, Stevens J, Binns J, Savitz AT, Garson SL, Fox SV et al (2014). Orexin receptor antagonist-induced sleep does not impair the ability to wake in response to emotionally salient acoustic stimuli in dogs. Front Behav Neurosci 8: 182.
Thannickal T, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M et al (2000). Reduced number of hypocretin neurons in human narcolepsy. Neuron 27: 469–474.
Uslaner JM, Tye SJ, Eddins DM, Wang X, Fox SV, Savitz AT et al (2013). Orexin receptor antagonists differ from standard sleep drugs by promoting sleep at doses that do not disrupt cognition. Sci Transl Med 5: 179ra144.
Vanover KE, Edgar DM, Seidel WF, Hogenkamp DJ, Fick DB, Lan NC et al (1999). Response-rate suppression in operant paradigm as predictor of soporific potency in rats and identification of three novel sedative-hypnotic neuroactive steroids. J Pharmacol Exp Ther 291: 1317–1323.
Vazquez-DeRose J, Schwartz MD, Nguyen AT, Warrier DR, Gulati S, Mathew TK et al (2014). Hypocretin/orexin antagonism enhances sleep-related adenosine and GABA neurotransmission in rat basal forebrain. Brain Structure Funct (e-pub ahead of print).
Verster JC, Veldhuijzen DS, Patat A, Olivier B, Volkerts ER (2006). Hypnotics and driving safety: meta-analyses of randomized controlled trials applying the on-the-road driving test. Curr Drug Safety 1: 63–71.
Wesensten NJ, Balkin TJ, Belenky GL (1995). Effects of daytime administration of zolpidem versus triazolam on memory. Eur J Clin Pharmacol 48: 115–122.
Wesensten NJ, Balkin TJ, Belenky GL (1996). Effects of daytime administration of zolpidem and triazolam on performance. Aviation Space Environ Med 67: 115–120.
Wesensten NJ, Balkin TJ, Reichardt RM, Kautz MA, Saviolakis GA, Belenky G (2005). Daytime sleep and performance following a zolpidem and melatonin cocktail. Sleep 28: 93–103.
Winrow CJ, Gotter AL, Cox CD, Doran SM, Tannenbaum PL, Breslin MJ et al (2011). Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist. J Neurogenet 25: 52–61.
Yamanaka A, Tsujino N, Funahashi H, Honda K, Guan JL, Wang QP et al (2002). Orexins activate histaminergic neurons via the orexin 2 receptor. Biochem Biophys Res Commun 290: 1237–1245.
Yoshida K, McCormack S, Espana RA, Crocker A, Scammell TE (2006). Afferents to the orexin neurons of the rat brain. J Comp Neurol 494: 845–861.
Acknowledgements
Research supported by USAMRAA Grant DR080789P1, DFG fellowship DI 1718/1-1, and NIH R01 NS077408. We thank Alan Wilk, Michael Miller, and Webster Lincoln for assistance with the experiments and Rhiannan Williams for editorial assistance.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Neuropsychopharmacology website
Rights and permissions
About this article
Cite this article
Parks, G., Warrier, D., Dittrich, L. et al. The Dual Hypocretin Receptor Antagonist Almorexant is Permissive for Activation of Wake-Promoting Systems. Neuropsychopharmacol 41, 1144–1155 (2016). https://doi.org/10.1038/npp.2015.256
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/npp.2015.256
This article is cited by
-
Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia
Psychopharmacology (2021)
-
Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders
Neuroscience Bulletin (2020)
-
The natural Disc1-deletion present in several inbred mouse strains does not affect sleep
Scientific Reports (2017)
-
Orexin Receptor Antagonists
Current Sleep Medicine Reports (2017)
